Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01341184 · ClinicalTrials.gov registry record · Phase 1
TMC207 +/- Rifabutin/Rifampin
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01341184 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 33 participants.
The verdict
NCT01341184, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Evaluation of effect of rifampin or rifabutin on single dose PK of TMC207 in healthy volunteers
Interventions
- DRUG Rifampin
- DRUG Rifabutin
- DRUG TMC207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-10-21 |
| Est. Completion | 2012-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01341184
The ClinicalTrials.gov registry entry for NCT01341184 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT01341184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01341184 about?
NCT01341184 is a clinical study titled "TMC207 +/- Rifabutin/Rifampin". Evaluation of effect of rifampin or rifabutin on single dose PK of TMC207 in healthy volunteers
What is the current status of trial NCT01341184?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2011-10-21. Estimated completion is 2012-05-23.
What interventions are being tested in trial NCT01341184?
The interventions under investigation include: Rifampin (DRUG), Rifabutin (DRUG), TMC207 (DRUG).
Who is sponsoring clinical trial NCT01341184?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.